---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-188532"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2023-07-18T23:59:59+00:00"
generated_at: "2026-06-13T07:22:42.258165+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Novartis discontinues Phase 3 trial of XOMA-licensed NIS793 in pancreatic cancer; continues in colorectal cancer

## Summary
- Novartis stopped Phase 3 trial (NCT04935359) of NIS793 in first-line metastatic PDAC based on benefit-risk assessment.
- Trial compared NIS793 plus gem/nab-paclitaxel vs placebo plus gem/nab-paclitaxel; no efficacy or safety established.
- Novartis will continue investigating NIS793 in other indications, including a Phase 2 study in colorectal cancer.
- XOMA licensed NIS793 to Novartis in September 2015 under a license agreement previously filed with the SEC.

## SEC filing metadata
- accession: 0001193125-23-188532
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2023-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312523188532/0001193125-23-188532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312523188532/d509906d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-188532
- JSON: https://secwatch.observer/filing/0001193125-23-188532.json
- Plain text: https://secwatch.observer/filing/0001193125-23-188532.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.